<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306721</url>
  </required_header>
  <id_info>
    <org_study_id>EFC11243</org_study_id>
    <secondary_id>U1111-1115-7613</secondary_id>
    <nct_id>NCT01306721</nct_id>
  </id_info>
  <brief_title>Fexofenadine HCL - Pseudoephedrine HCL Combination Versus Allegra in Patients With Seasonal Allergic Rhinitis</brief_title>
  <official_title>A Randomized, Double Blind, Parallel Group Study for Assessing the Efficacy and Safety of a Twice-daily Fexofenadine HCl 60 mg - Pseudoephedrine HCl 60 mg Combination or Fexofenadine HCl 60 mg - Pseudoephedrine HCl 120 mg Combination Versus AllegraÂ® 60 mg in Patients With Seasonal Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      - To evaluate the efficacy on the nasal congestion of a twice-daily fexofenadine HCl 60 mg -
      pseudoephedrine HCl 60 mg combination (FEX60/PSE60) and fexofenadine HCl 60 mg -
      pseudoephedrine HCl 120 mg combination (FEX60/PSE120) versus fexofenadine HCl 60 mg (FEX60)
      in patients with seasonal allergic rhinitis (SAR).

      Secondary Objectives:

        -  To evaluate the efficacy of a twice-daily FEX60/PSE60 and FEX60/PSE120 versus FEX60 on
           nasal symptoms (sneezing, rhinorrhea, and nasal congestion), eye symptom, and daily
           activity impairment.

        -  To assess the safety of a twice-daily FEX60/PSE60 and FEX60/PSE120 versus FEX60.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration for each patient is 3 weeks and 3 days:

        1. Lead-in period: 1 week

        2. Treatment period: 2 weeks

        3. Follow-up period: 3 days
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the nasal congestion score based on the patient's symptom diary</measure>
    <time_frame>over 2 treatment weeks (from baseline to end of treatment)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the total score of 4 symptoms, each nasal symptom (sneezing, rhinorrhea, and nasal congestion) and eye symptom</measure>
    <time_frame>over 2 treatment weeks (from baseline to end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total score of 4 symptoms on a daily, day-time, and night-time bases</measure>
    <time_frame>over 2 treatment weeks (from baseline to end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in each symptom (sneezing, rhinorrhea, nasal congestion, and eye symptoms) score and the daily activity impairment score</measure>
    <time_frame>over 2 treatment weeks (from baseline to end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in each symptom score and the daily activity impairment score on a daily, day-time and night-time basis</measure>
    <time_frame>over 2 treatment weeks (from baseline to end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal findings</measure>
    <time_frame>over 2 treatment weeks (from baseline to end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's impression</measure>
    <time_frame>over 2 treatment weeks (from baseline to end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's safety</measure>
    <time_frame>over 2 treatment weeks (from baseline to end of treatment)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">520</enrollment>
  <condition>Rhinitis Seasonal</condition>
  <arm_group>
    <arm_group_label>FEX 60 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study medications is administered one hour before or two hours after a meal twice a day.
Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination)
Double-blind treatment period:
1 tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg /pseudoephedrine 60 mg (fixe dose combination)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FEX 60 mg/PSE 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study medications is administered one hour before or two hours after a meal twice a day.
Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination
Double-blind treatment period:
1 tablet of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 60 mg / pseudoephedrine 60 mg (fixe dose combination)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FEX 60 mg/PSE 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study medications is administered one hour before or two hours after a meal twice a day.
Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination)
Double-blind treatment period:
2 tablets of fexofenadine 30 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 30 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fexofenadine HCL (M016455)</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>FEX 60 mg</arm_group_label>
    <arm_group_label>FEX 60 mg/PSE 60 mg</arm_group_label>
    <arm_group_label>FEX 60 mg/PSE 120 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pseudoephedrine</intervention_name>
    <description>Pharmaceutical form:tablet
Route of administration: oral</description>
    <arm_group_label>FEX 60 mg</arm_group_label>
    <arm_group_label>FEX 60 mg/PSE 60 mg</arm_group_label>
    <arm_group_label>FEX 60 mg/PSE 120 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fexofenadine HCL matching placebo</intervention_name>
    <description>Pharmaceutical form:tablet
Route of administration: oral</description>
    <arm_group_label>FEX 60 mg</arm_group_label>
    <arm_group_label>FEX 60 mg/PSE 60 mg</arm_group_label>
    <arm_group_label>FEX 60 mg/PSE 120 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pseudoephedrine matching placebo</intervention_name>
    <description>Pharmaceutical form:tablet
Route of administration: oral</description>
    <arm_group_label>FEX 60 mg</arm_group_label>
    <arm_group_label>FEX 60 mg/PSE 60 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        - Patients with seasonal allergic rhinitis (SAR): Patients with a history of SAR symptoms
        during the season when cedar pollen levels are increased for at least 2-years

        Exclusion criteria:

          -  At the start of the placebo lead-in period:

               -  Patients who are negative for IgE Antibody test

               -  Expected nasal congestion score is less than 2

          -  The last 3 days of the lead-in period:

               -  Nasal congestion scores are 2 or more and not all 4

               -  Patients with all nasal symptoms (sneezing, rhinorrhea, and nasal congestion). A
                  total score for nasal symptoms (sneezing, rhinorrhea, and nasal congestion) and
                  eye symptom is less than 6

               -  Patients with 2 or more nasal symptoms (sneezing and rhinorrhea) and eye symptoms
                  score is 4

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 392002</name>
      <address>
        <city>Koganei-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392003</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392001</name>
      <address>
        <city>Shinjuku-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2011</study_first_submitted>
  <study_first_submitted_qc>March 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <last_update_submitted>October 12, 2013</last_update_submitted>
  <last_update_submitted_qc>October 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Terfenadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

